| Recruiting | Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis NCT07339085 | Jonsson Comprehensive Cancer Center | N/A |
| Withdrawn | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer NCT05840770 | City of Hope Medical Center | Phase 2 |
| Recruiting | Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has NCT06500455 | NRG Oncology | Phase 3 |
| Recruiting | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectabl NCT06650163 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Recruiting | Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases NCT06328686 | Emory University | EARLY_Phase 1 |
| Withdrawn | Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer Wit NCT06137651 | Northwestern University | Phase 1 |
| Terminated | An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improvi NCT06315296 | Thomas Jefferson University | N/A |
| Recruiting | Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Met NCT05588453 | Kari Kendra | Phase 1 / Phase 2 |
| Recruiting | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brai NCT05376878 | City of Hope Medical Center | Phase 4 |
| Recruiting | Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple NCT04348747 | Roswell Park Cancer Institute | Phase 2 |
| Active Not Recruiting | Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases NCT05438212 | NRG Oncology | Phase 3 |
| Terminated | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic NCT05388877 | Mayo Clinic | Phase 1 |
| Active Not Recruiting | Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Bra NCT05341349 | Emory University | Phase 1 |
| Active Not Recruiting | Neuropsychological Care for Maintaining Quality of Life After Radiation Therapy in Patients With Brain Metasta NCT05503251 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Active Not Recruiting | Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic B NCT05139043 | City of Hope Medical Center | Phase 2 |
| Recruiting | SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial NCT05222620 | Mayo Clinic | Phase 2 |
| Terminated | Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery NCT04588246 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Radiosurgery Before Surgery for the Treatment of Brain Metastases NCT04895592 | Emory University | EARLY_Phase 1 |
| Terminated | 7T MRI Scan for the Early Detection of Melanoma Brain Metastases NCT04941430 | University of Southern California | N/A |
| Recruiting | Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids NCT04804644 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases NCT04647916 | SWOG Cancer Research Network | Phase 2 |
| Completed | Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment NCT04631029 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso NCT04460937 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases NCT04752267 | University of Southern California | EARLY_Phase 1 |
| Terminated | Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases NCT04789668 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab i NCT04511013 | SWOG Cancer Research Network | Phase 2 |
| Active Not Recruiting | Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-s NCT04250545 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis NCT04516070 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology NCT04988009 | M.D. Anderson Cancer Center | — |
| Withdrawn | Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Recep NCT04585724 | Emory University | Phase 1 |
| Completed | Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions NCT04132843 | M.D. Anderson Cancer Center | N/A |
| Recruiting | Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies NCT04047264 | Mayo Clinic | N/A |
| Active Not Recruiting | Single Fraction Stereotactic Radiosurgery Compared With Fractionated Stereotactic Radiosurgery in Treating Pat NCT04114981 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Active Not Recruiting | Genetic Testing in Guiding Treatment for Patients With Brain Metastases NCT03994796 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Active Not Recruiting | nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex NCT04062305 | M.D. Anderson Cancer Center | N/A |
| Withdrawn | Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Ca NCT03868423 | Sameek Roychowdhury | Phase 2 |
| Completed | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain NCT03873818 | M.D. Anderson Cancer Center | Phase 2 |
| Withdrawn | A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer NCT03803761 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Utility of Perfusion MRI to Detect Radiation Necrosis in Patients With Brain Metastases NCT03680144 | Emory University | N/A |
| Recruiting | Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain NCT03750227 | Mayo Clinic | Phase 3 |
| Recruiting | Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases NCT03741673 | M.D. Anderson Cancer Center | Phase 3 |
| Active Not Recruiting | HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases NCT03696030 | City of Hope Medical Center | Phase 1 |
| Completed | DECT in Imaging Patients With Solid Organ Cancer With Intracranial Metastasis NCT03685539 | M.D. Anderson Cancer Center | N/A |
| Completed | Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell NCT03520842 | Stanford University | Phase 2 |
| Completed | Dual Time Point FDG PET/MRI Scan in Improving the Imaging Cancer Patients With Brain Metastases NCT05054998 | M.D. Anderson Cancer Center | Phase 4 |
| Completed | STAT3 Inhibitor WP1066 in Treating Patients With Recurrent Malignant Glioma or Progressive Metastatic Melanoma NCT01904123 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and NCT02971501 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk NCT03418961 | SWOG Cancer Research Network | Phase 3 |
| Recruiting | Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System NCT03270059 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Blood Brain Barrier Differences in Patients with Brain Tumors Undergoing Surgery NCT03071913 | Mayo Clinic | — |
| Active Not Recruiting | Mind-Body Intervention in Glioma Couples NCT03244995 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Me NCT03175432 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment NCT02589522 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases NCT02993146 | National Cancer Institute (NCI) | Phase 1 |
| Completed | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid NCT03087591 | Wake Forest University Health Sciences | Phase 1 |
| Terminated | Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes NCT02774291 | Albert Einstein College of Medicine | EARLY_Phase 1 |
| Recruiting | Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery NCT03184038 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | N/A |
| Active Not Recruiting | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non NCT02696993 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutate NCT02910700 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases NCT02858869 | Emory University | Phase 1 |
| Completed | Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or B NCT02595905 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Frameless Fractionated Stereotactic Radiation in Treating Patients With Brain Metastases NCT02798029 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors NCT02754544 | M.D. Anderson Cancer Center | N/A |
| Completed | SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine NCT02716948 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Completed | Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neuroco NCT02360215 | NRG Oncology | Phase 3 |
| Active Not Recruiting | Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases NCT02015117 | National Cancer Institute (NCI) | Phase 1 |
| Completed | PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stag NCT02073968 | Albert Einstein College of Medicine | Phase 2 |
| Completed | Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Pa NCT01622868 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors NCT02167204 | University of Washington | N/A |
| Active Not Recruiting | Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases NCT01644591 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melan NCT01592968 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients Wi NCT02967380 | University of Southern California | N/A |
| Terminated | RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metas NCT01217411 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Stereotactic Radiosurgery Compared to Observation in Treating Patients With Brain Metastases NCT00950001 | M.D. Anderson Cancer Center | Phase 3 |
| Terminated | Ferumoxytol- and Gadolinium-Labeled MRI in Measuring Tumors Before or After Treatment in Patients With Primary NCT00659126 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients NCT00096265 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases NCT00103038 | OHSU Knight Cancer Institute | N/A |